Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume -, Issue -, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00528-23
Keywords
new treatment alternatives; minimum inhibitory concentrations; beta-lactam antibiotics; beta-lactamase inhibitors; difficult to treat NTMs; imipenem-relebactam; tebipenem-avibactam
Categories
Ask authors/readers for more resources
This study found that adding relebactam to imipenem and avibactam to tebipenem significantly reduced the minimum inhibitory concentrations (MICs) against MABC. These findings suggest that these novel carbapenem combinations could be potential non-toxic, oral treatment options for MABC.
As new treatment alternatives for Mycobacterium abscessus complex (MABC) are urgently needed, we determined the minimum inhibitory concentrations (MICs) for novel carbapenem combinations, including imipenem-relebactam and tebipenem-avibactam against 98 MABC isolates by broth microdilution. The MIC50 was reduced from 16 to 8 mg/L by adding relebactam to imipenem, while the addition of avibactam to tebipenem showed a more pronounced reduction from 256 to 16 mg/L, representing a promising non-toxic, oral treatment option for further exploration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available